Matches in SemOpenAlex for { <https://semopenalex.org/work/W3149449008> ?p ?o ?g. }
- W3149449008 endingPage "170" @default.
- W3149449008 startingPage "158" @default.
- W3149449008 abstract "Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials. However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab’s antibody-dependent cellular cytotoxicity (ADCC) efficacy. Orelabrutinib (Orel), a novel BTK inhibitor, was designed with high selectivity to BTK. In our study, we demonstrated in preclinical models that orelabrutinib in combination with rituximab could preserve NK-cell-mediated ADCC induced by rituximab and enhanced the apoptosis of tumor cells in vitro. The addition of orelabrutinib to rituximab had produced promising combined anti-tumor effects in B cell lymphomas in vivo. Collectively, combination therapy of orelabrutinib with rituximab would benefit patients with B cell lymphoma, especially those with relapsed or refractory disease. Bruton tyrosine kinase (BTK) inhibitor ibrutinib has been validated as an effective drug to treat B cell malignancies. Combined therapies comprising ibrutinib and anti-CD20 antibodies like rituximab were designed as a backbone in many clinical trials. However, the off-target inhibition of ibrutinib on interleukin-2 (IL-2)-inducible T cell kinase (ITK) may reduce rituximab’s antibody-dependent cellular cytotoxicity (ADCC) efficacy. Orelabrutinib (Orel), a novel BTK inhibitor, was designed with high selectivity to BTK. In our study, we demonstrated in preclinical models that orelabrutinib in combination with rituximab could preserve NK-cell-mediated ADCC induced by rituximab and enhanced the apoptosis of tumor cells in vitro. The addition of orelabrutinib to rituximab had produced promising combined anti-tumor effects in B cell lymphomas in vivo. Collectively, combination therapy of orelabrutinib with rituximab would benefit patients with B cell lymphoma, especially those with relapsed or refractory disease." @default.
- W3149449008 created "2021-04-13" @default.
- W3149449008 creator A5007888237 @default.
- W3149449008 creator A5027714830 @default.
- W3149449008 creator A5029851581 @default.
- W3149449008 creator A5030040961 @default.
- W3149449008 creator A5048010041 @default.
- W3149449008 creator A5063922467 @default.
- W3149449008 creator A5066795023 @default.
- W3149449008 creator A5068544203 @default.
- W3149449008 creator A5078269576 @default.
- W3149449008 creator A5082343726 @default.
- W3149449008 creator A5083415672 @default.
- W3149449008 date "2021-06-01" @default.
- W3149449008 modified "2023-10-14" @default.
- W3149449008 title "Addition of BTK inhibitor orelabrutinib to rituximab improved anti-tumor effects in B cell lymphoma" @default.
- W3149449008 cites W1600391089 @default.
- W3149449008 cites W1953964769 @default.
- W3149449008 cites W1970264918 @default.
- W3149449008 cites W1979816280 @default.
- W3149449008 cites W2004739040 @default.
- W3149449008 cites W2013909810 @default.
- W3149449008 cites W2018571395 @default.
- W3149449008 cites W2030263904 @default.
- W3149449008 cites W2062457956 @default.
- W3149449008 cites W2071549499 @default.
- W3149449008 cites W2089103836 @default.
- W3149449008 cites W2107820445 @default.
- W3149449008 cites W2128402413 @default.
- W3149449008 cites W2131823788 @default.
- W3149449008 cites W2133192145 @default.
- W3149449008 cites W2142604595 @default.
- W3149449008 cites W2145304413 @default.
- W3149449008 cites W2150487985 @default.
- W3149449008 cites W2154066874 @default.
- W3149449008 cites W2162305597 @default.
- W3149449008 cites W2165090528 @default.
- W3149449008 cites W2171771895 @default.
- W3149449008 cites W2233614027 @default.
- W3149449008 cites W2316021978 @default.
- W3149449008 cites W2327407534 @default.
- W3149449008 cites W2508017542 @default.
- W3149449008 cites W2557596611 @default.
- W3149449008 cites W2604220612 @default.
- W3149449008 cites W2734526350 @default.
- W3149449008 cites W2745356721 @default.
- W3149449008 cites W2755070616 @default.
- W3149449008 cites W2763676229 @default.
- W3149449008 cites W2763953131 @default.
- W3149449008 cites W2787835497 @default.
- W3149449008 cites W2884660389 @default.
- W3149449008 cites W2943904368 @default.
- W3149449008 cites W2949584172 @default.
- W3149449008 cites W2991411365 @default.
- W3149449008 cites W3008384403 @default.
- W3149449008 cites W3119726016 @default.
- W3149449008 cites W3134746818 @default.
- W3149449008 doi "https://doi.org/10.1016/j.omto.2021.03.015" @default.
- W3149449008 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8082047" @default.
- W3149449008 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33981831" @default.
- W3149449008 hasPublicationYear "2021" @default.
- W3149449008 type Work @default.
- W3149449008 sameAs 3149449008 @default.
- W3149449008 citedByCount "17" @default.
- W3149449008 countsByYear W31494490082022 @default.
- W3149449008 countsByYear W31494490082023 @default.
- W3149449008 crossrefType "journal-article" @default.
- W3149449008 hasAuthorship W3149449008A5007888237 @default.
- W3149449008 hasAuthorship W3149449008A5027714830 @default.
- W3149449008 hasAuthorship W3149449008A5029851581 @default.
- W3149449008 hasAuthorship W3149449008A5030040961 @default.
- W3149449008 hasAuthorship W3149449008A5048010041 @default.
- W3149449008 hasAuthorship W3149449008A5063922467 @default.
- W3149449008 hasAuthorship W3149449008A5066795023 @default.
- W3149449008 hasAuthorship W3149449008A5068544203 @default.
- W3149449008 hasAuthorship W3149449008A5078269576 @default.
- W3149449008 hasAuthorship W3149449008A5082343726 @default.
- W3149449008 hasAuthorship W3149449008A5083415672 @default.
- W3149449008 hasBestOaLocation W31494490082 @default.
- W3149449008 hasConcept C126322002 @default.
- W3149449008 hasConcept C159654299 @default.
- W3149449008 hasConcept C170493617 @default.
- W3149449008 hasConcept C18031839 @default.
- W3149449008 hasConcept C203014093 @default.
- W3149449008 hasConcept C2777938653 @default.
- W3149449008 hasConcept C2778453870 @default.
- W3149449008 hasConcept C2778461978 @default.
- W3149449008 hasConcept C2779338263 @default.
- W3149449008 hasConcept C2779878957 @default.
- W3149449008 hasConcept C2780653079 @default.
- W3149449008 hasConcept C40677261 @default.
- W3149449008 hasConcept C42362537 @default.
- W3149449008 hasConcept C502942594 @default.
- W3149449008 hasConcept C542903549 @default.
- W3149449008 hasConcept C71924100 @default.
- W3149449008 hasConcept C90059517 @default.
- W3149449008 hasConcept C98274493 @default.
- W3149449008 hasConceptScore W3149449008C126322002 @default.